TTR and cardiac amyloidosis: For example, the study aimed to evaluate Eplontersen for transthyretin-mediated amyloid cardiomyopathy, which has the abbreviation CARDIO-TTRANSform (CARDIO-TTRansform 2023: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), n.d.), implying a transformative therapy.